Position in NUVL
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$13,455,448
New position
Shares Held
108,951
first reported quarter
Ownership
0.138%
of shares outstanding
% of Portfolio
5.68%
of 13F equity value
Holder Rank
#1
of 6 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $19,945,542 across 57 Biotechnology names. NUVL ranks #1 (67.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NUVL |
Nuvalent, Inc.
This page
|
108,951 | $13,455,448 | |
| 2 | ABVX |
Abivax S.A.
|
7,605 | $1,013,442 | |
| 3 | SGMT |
Sagimet Biosciences Inc.
|
109,250 | $844,502 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
5,000 | $663,650 | |
| 5 | JANX |
Janux Therapeutics, Inc.
|
30,850 | $473,856 | |
| 6 | NKTR |
Nektar Therapeutics
|
5,500 | $383,955 | |
| 7 | VERU |
Veru Inc.
|
105,081 | $328,903 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
8,170 | $318,711 |
All Filings in NUVL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,455,448 | 108,951 | Shares | Defined | 2026-07-08 | |
| No filing history on record for this holder in this stock. | ||||||